## Neoadjuvant systemic therapy for MIBC

**Thomas Powles** 

Director of Barts Cancer Center. Professor of Urology Cancer, Barts Cancer Institute.




## DISCLOSURES

Reaserch funding/honoraria/travel costs:

## MSD, Merck, Pfizer, GSK, Novartis, Roche, AZ, BMS, Exelexis, Ipsen, Seattle Genetics, Esai, Genentech.


	Study arm	endpoint	OS HR	OS outcome
DANUBE	Durvalumab	PD-L1+ve	0.89	-ve
	Durvalumab/tremilimumab	ITT	0.85	-ve
IMVIGOR	atezolizumab	PD-L1+ve	0.68	Awaited
130	Atezolizumab/chemotherapy	ITT	0.83	Awaited
KEYNOTE 361	pembrolizumab	PD-L1+ve	1.01	-ve
	Pembrolizumab/chemotherapy	ITT	0.86	-ve
JAVELIN100	Avelumab maintenance	ITT	0.69	+ve
CHECKMATE	Ipilimumab/nivolumab	PD-L1+ve	NA	-ve
901	Chemotherapy/nivolumab	ITT		Awaited
NILE	Chemotherapy/durva/tremi			Awaited
	Chemotherapy/durvalumab			Awaited

#### PEMBROLIZUMAB + ENFORTUMAB VEDOTIN IN FIRST LINE PLATINUM INELIGIBLE DISEASE



PD-L1 tested using the 22C3 PharmDx assay from Agilent/Dako

Non randomised study for nivolumab and ipilimumab combinations in platinum refractory UC showing good outcome for the PD-L1+ve with Ipi3 nivo1




### FGFR inhibition (rogaratinib) vs chemotherapy in FGFR+ve platinum refractory UC


Response rate	25%	
Biomarker method	RNA FGFR 1+3	
% biomarker positive	68% +ve	
Toxicity	43% grade 3/4 toxicity	
Toxicity type	Hyperphosphatemia	

#### Other FGFR inhibitors (single arm trials)

Drug	Biomarker	RR + PFS
Erdafitinib (n=99)	FGFR3 PCR	40% + 5.5 mnths
AZD4547 (n=16)	FGFR2/3 DNA	31% +4.5 months
BGJ398 (n=67)	FGFR3	25%
INDB05842 (n=100)	FGFR3 DNA	25%



A brief overview for biomarkers for PD (L)1 therapy in UC



Learning points from advanced disease to consider in perioperative setting

The chemotherapy combinations with immune therapy appears antagonistic.

The biomarkers are a mess


EV appears to combine will with immune therapy

CTLA-4 and FGFR have activity in UC, but we don't know how much

Duration of immune therapy and ADCs are unclear.

#### Adjuvant atezolizumab and nivolumab in UC

CheckMate 274



#### Disease-free survival in select subgroups: ITT patients


Subgroup	Nivolumab	Placebo	HR (95% CI)	
	no. of e	events/	, ,	
	no. of p			
Initial tumor origin	,,,			
Urinary bladder	126/279	165/281	0.62 (0.49-0.78)	(
Renal pelvis	23/44	25/52	1.16 (0.63-2.13)	
Ureter	17/30	13/23	1.55 (0.70-3.45)	
Pathologic lymph node status				
N+	95/167	115/168	0.65 (0.49-0.86)	<b>_</b>
N0/x with < 10 nodes removed	44/94	50/99	0.82 (0.54-1.24)	
N0 with $\geq$ 10 nodes removed	27/91	37/88	0.64 (0.39-1.06)	
Pathologic status			· · · · · ·	
pT0-2	36/80	40/86	0.93 (0.58-1.51)	
рТ3	94/206	119/204	0.62 (0.47-0.82)	<b> </b>
pT4a	34/57	40/62	0.74 (0.45-1.21)	
Prior neoadjuvant cisplatin				
Yes	69/153	99/155	0.53 (0.39-0.72)	
No	97/200	104/201	0.89 (0.67-1.18)	
Baseline PD-L1 expression			Charles Section - Herbored Proven - Herbored Section	
≥ 1%	52/139	78/141	0.55 (0.39-0.78)	i
< 1%	113/210	120/209	0.82 (0.63-1.06)	
Time from IUC surgery to			ona mozzon - a centro visit i mozzon v - mozzone mozen	
randomization, days				I I
> 30-60	43/79	39/70	0.70 (0.43-1.12)	
> 60-90	76/165	93/177	0.73 (0.53-1.00)	
> 90-120	45/103	62/95	0.64 (0.42-0.96)	
			· · · ·	
			0.1	1 10
				NIVO better   PBO better

### DFS by Clinical Subgroup

Median DFS, mo

Population (n)	Atezolizumab (N = 406)	Observation (N = 403)		DFS HR (95% CI) <sup>c</sup>
All patients (809)	19.4	16.6		0.93 (0.76, 1.12)
Bladder (755)	19.6	15.8		0.91 (0.74, 1.10)
Upper tract (ureter, renal pelvis) (54)	14.2	28.1	► • • • • • • • • • • • • • • • • • • •	1.25 (0.57, 2.74)
Prior neoadjuvant chemotherapy (385) <sup>a</sup>	19.8	16.5		0.87 (0.66, 1.15)
Positive pathologic node status (420) <sup>a</sup>	13.9	8.9		0.93 (0.73, 1.19)
pT2N0 (73) <sup>b</sup>	NE	NE	◆ · · · · · · · · · · · · · · · · · · ·	1.57 (0.71, 3.46)
pT3N0 (243) <sup>b</sup>	NE	24.9		0.83 (0.56, 1.23)
pT4N0 (65) <sup>b</sup>	NE	14.2	•	0.60 (0.29, 1.25)
Asia (125)	23.1	24.8		0.96 (0.57, 1.61)
Europe (437)	19.1	12.3		0.93 (0.72, 1.19)
North America (241)	19.8	16.5		0.88 (0.62, 1.26)
Australian subgroups not shown (n = 6). NE, not evaluable. <sup>a</sup> Per IxRS. <sup>b</sup> Per eCRF. <sup>c</sup> Unstratified analyses.		0.25	1.0 2.5 Atezolizumab better Observation better	<b>→</b>

# The only OS data for immune therapy in adjuvant bladder cancer



Data cutoff: November 30, 2019. Median follow-up: 21.9 mo. Most common subsequent non-protocol therapies included immunotherapy (9% in atezolizumab arm vs 21% in observation arm), chemotherapy (27% vs 25%) and targeted therapy (5% vs 2%). <sup>a</sup> OS results are shown for descriptive purposes only. HR stratified by tumor stage, nodal status and PD-L1 status.

#### Why have the agencies gone in different direction





#### uncertainty

<u>noun</u>

Save Word

To save this word, you'll need to log in.


Log In

## un·cer·tain·ty | \ ,ən-'sər-tən-tē \ **Definition of** *uncertainty*

**1**: the quality or state of being <u>uncertain</u> : <u>DOUBT</u>

2: something that is uncertain

#### **Evaluation of ctDNA**



- 1. Tumour tissue and germline material were sequenced (whole exome sequencing)
- 2. Up to 16 mutations for personalised mPCR ctDNA assay were identified for each patient
- Plasma samples were sequenced to ≈100,000×
- If ≥2 mutations were detected, sample was defined as ctDNA(+)
- 5. MRD sample timepoint before adjuvant treatment (C1D1) was collected
- 6. On-treatment sample (C3D1; week 6) was also collected

### Phase 3 IMvigor010 adjuvant study in MIUC



- High-risk MIUC (bladder or upper tract)
- Radical surgery with lymph node dissection within ≤14 weeks
- Tissue sample for PD-L1 testing




#### **Endpoints**

- Primary: DFS (ITT population)
- Key secondary: OS (ITT population)
- Other: Safety
- Exploratory: predictive, prognostic and pharmacodynamic biomarkers in tumour tissue and blood and their association with disease recurrence

- IMvigor010 did not meet its primary endpoint (DFS in the ITT population)<sup>1</sup>
  - A pre-planned interim OS analysis was performed but could not be formally tested
  - OS follow-up is immature and ongoing in the ITT population
- The PD-L1 and TMB biomarkers did not identify patients benefitting from atezolizumab vs observation in the ITT population
- A pre-specified ctDNA biomarker analysis was performed Powles et al. IMvigor010 ctDNA https://bit.ly/2lxYllE


### ctDNA(+) patients have poor prognosis




• IMvigor010 confirmed the prognostic value of ctDNA status

Powles et al. IMvigor010 ctDNA https://bit.ly/2lxYllE


## ctDNA(+) patients in the BEP had improved DFS and OS with atezolizumab vs observation



Adjuvant Atezolizumab vs Placebo in High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)




## A phase III trial of dd-MVAC or Gemcitabine and Cisplatin as perioperative treatment in muscle-invasive bladder cancer (MIBC). Christian Pfister



 Pathological response (neoadjuvant CT +cystectomy performed only)

 GC
 dd-MVAC


 ypT0 N0
 71 (36%)
 84 (42%)



#### A phase III trial of dd-MVAC or Gemcitabine and Cisplatin as perioperative treatment in muscle-invasive bladder cancer (MIBC).

Pathological response (neoadjuvant CT +cystectomy performed only)				
	GC	dd-MVAC		
ypT0 N0	71 (36%)	84 (42%)		

### PURE1 and ABACUS : Trial Design






#ASCO18 Slides are the property of the author, permission required for reuse.



## Pathological response rate in Abacus



ACR patient ACR patient PCR pa

PanCK-CD8


H&E stain

Pathological complete response

Major pathological response (90% necrosis + CD8 infiltration)

Remainder

## Immune therapy neoadjuvant trials.



Grossman et al. NEJM 2003 Flaig et al, CCR 2021 Gupta et al, JCO 38,6\_supp (Feb 2020). Necchi et al, JCO 2018 Grivas et al, ASCO Annual Mtg 2021; abstr 4518 EORTC 30894, JCO 2011 Rose et al, GU ASCO 2021, abstr 396. Cathomas et al, GU ASCO 2021, abstr 430. Powles et al, Nat Med 2019 Kaimakliotis et al, ASCO Annual Pfister et al, Euro Urol 2021 Hoimes et al, ESMO 2018, abstr 5681. Funt et al, ASCO Annual Meeting, abstr 4517. Van Dijk et al, ASCO Annual Mtg 2020;abstr 5020

## What about DFS and OS endpoint.

	2y PFS/EFS	2y OS
VESPER		
dd-MVAC	~ 77%	~ 88%
GC	~ 62%	~ 79%
SAKK		
GC-D	76%	87%
ABACUS	68%	77%
PURE1	73%	91%

#### **ASCO-GU22 Update: New players**



EV-103 Cohort H Study Design Eligibility **Cisplatin-ineligible** Neoadjuvant EV **Clinical stage** Radical T2-T4aN0M0 monotherapy Follow-Up Imaging cystectomy an x 3 cycles Q12W for the first 2 pelvic lymph No upper tract or 1.25 mg/kg of EV on urethral tumors allowed D1 and D8 node dissectio Imaging of 21-day cycle Pre-RIC Imag >50% Urothelial carcinoma histology 4 to 12 weeks after las dase of neoadjuvant E ECOG 0-2 Medically fit for RC+PLND Primary endpoint: pCR rate by central pathology review TURBT ≤90 days from C1D1 Secondary endpoints: pDS rate (central review), EFS, DFS, OS, safety, PROs, biomarkers


	Cohort H (N=22)
Male sex, n (%)	20 (90.9)
Median age (range), years	74.5 (56-81)
White race, n (%)	22 (100)
Current or former smoker, n (%)	21 (95.5)
Median enrollment time from diagnosis (range), months	1.6 (1-3)
ECOG performance status	
0	13 (59.1)
1	8 (36.4)
2	1 (4:5)
Current stage, n (%)	
cT2N0	15 (68:2)
cT3N0	6 (27.3)
cT4aN0	1 (4.5)
Histology type, n (%)	
Transitional cell carcinoma (TCC) only	15 (68.2)
CC With squarkous differentiation	3 (13.6)
WAR with all as blatalents understa	4 1 4 40 - 55

Pathological Response	Central Pathology Results (N=22) n (%) [95% Confidence Interval]	
Pathological Complete Response Rate	<b>8 (36.4%)</b>	
(defined as absence of any viable tumor tissue: ypT0 and N0)	[17.2–59.3]	
Pathological Downstaging Rate	<b>11 (50.0%)</b>	
(defined as presence of ypT0, ypTis, ypTa, ypT1, and N0)	[28.2–71.8]	

Petrylak DP, et al. J Clin Oncol. 40, 2022 (suppl 6; abstr 435)


#### **ASCO-GU22 Update: New players**






Petrylak Dr., ot al. o on or one of the Local poppl 6; abstr 435)

Non randomised study for nivolumab and ipilimumab combinations in platinum refractory UC showing good outcome for the PD-L1+ve with Ipi3 nivo1




Non randomised study for nivolumab and ipilimumab combinations in platinum refractory UC showing good outcome for the PD-L1+ve with Ipi3 nivo1



Randomised phase II of Nintedanib +/- Gemcitabine/Cisplatin in muscle invasive bladder cancer

- 24 month OS
  - Placebo: 69%
  - Nintedanib: 89%
- Hazard Ratio:
- 0.38 (0.16, 0.87); P=0.018



Prof. Syed A Hussain Lancet Oncol 22

## Perioperative trials fall in 4 broad groups.

#### Adjuvant therapy in unselected patients

- Atezolizumab
- Pembrolizumab
- Nivolumab

## Neoadjuvant therapy in cisplatin eligible patients

- Gemcitabline cisplatin + durvalumab
- Gemcitabline cisplatin + Pembrolizumab
- Enfortumab Vediton + pembrolizumab
- Gemcitabine + nivolumab + IDO


#### Adjuvant therapy in selected patients

• ctDNA to select for atezolizumab

## Neoadjuvant therapy in cisplatin ineligible/refusing patients

- Pembrolizumab
- Pembrolizumab + EV
- Durvalumab EV
- Durvalumab tremilimumab EV

Are a few immunotherapy courses able to control the disease? Survival after short-course neoadjuvant IO and radical cystectomy



1. Van Dijk N, et al. *Nat Med.* 2020 Oct 12. doi: 10.1038/s41591-020-1085-z. 2. Powles T, et al. *Nature.* 2021 Jun 16. doi: 10.1038/s41586-021-03642-9. Online ahead of print. 3. Bandini M, et al. *Ann Oncol.* 2020 Dec;31(12):1755-1763.

### ctDNA and outcome during therapy (MTM mean)


post surgery

C1D1 PreCx firstPostCxSample 100 -10 meanMTM\_forLog 1 -. 0.1 -: [0-0.01] -RELAPSE RESPONDER RELÁPSE RESPONDER SD RELAPSE SD RESPONDER SD OUTCOME\_3CAT

post atezo

Baseline

#### Neoadjuvant trials for the future: Triplet personalized therapy with surgery sparing approaches. How can we do this?



## Conclusions

- Neoadjuvant cisplatin based chemotherapy is associated with a survival benefit
- Neoadjuvant immune checkpoint inhibitors holds much promise
- Tissue based biomarker discovery in this setting has not been consistent.
- Circulating biomarkers will advance the field.
- Adjuvant immune therapy and chemotherapy has become confusing
- There are 7 randomized phase III trials for immune therapy in the neoadjuvant setting asking different questions.